Washington Post: Two doses of Pfizer and AstraZeneca coronavirus vaccines effective against delta variant, study says

Washington Post: Two doses of Pfizer and AstraZeneca coronavirus vaccines effective against delta variant, study says. “Two doses of the Pfizer-BioNTech vaccine offer 88 percent protection against symptomatic disease caused by the delta variant, compared to 94 percent against the alpha variant that was first discovered in Britain and became dominant across the globe earlier this year, the study said. A double dose of the Oxford-AstraZeneca vaccine was 67 percent effective against delta, according to the British researchers, down slightly from an efficacy rate of 75 percent against the alpha variant.”

EurekAlert: Beautiful VR setting could reduce pain in unpleasant medical procedure

EurekAlert: Beautiful VR setting could reduce pain in unpleasant medical procedure. “Dr Wojciech Krajewski and colleagues at the Wroc?aw Medical University in Poland recruited 103 patients, with a mean age of 66 years, who were listed for rigid cystoscopy with just local, intraurethral anaesthesia. Some were for a first diagnosis and others required follow up having experienced the procedure in the past. Individuals were randomised to undergo classic cystoscopy or the procedure with VR goggles and headphones presenting an image of the Skógafoss waterfall in Iceland.”

Science: European law could improve ‘scandalous’ lack of clinical trial data reporting

Science: European law could improve ‘scandalous’ lack of clinical trial data reporting. “A total of 3846 European trials—nearly 28% of 13,874 completed trials in the EU Clinical Trials Register (EUCTR) on 1 July—had not posted their results on the register, according to the latest data from the EU Trials Tracker, set up by U.K. researchers in 2018 to expose lax reporting. Public research hospitals and universities, not drugmakers, are responsible for the vast majority of the lapses, which appear to violate European rules that require sponsors to post their results within 1 year of a trial’s conclusion.”

EurekAlert: New Web Tool Fights Antibacterial Resistance

EurekAlert: New Web Tool Fights Antibacterial Resistance. “In 1943, two scientists named Max Delbrück and Salvador Luria conducted an experiment to show that bacteria can mutate randomly, independent of external stimulus, such as an antibiotic that threatens a bacterial cells’ survival. Today the Luria-Delbrück experiment is widely used in laboratories for a different purpose–scientists use this classic experiment to determine microbial mutation rates. When performing the Luria-Delbrück experiment, scientists need efficient computer algorithms to extract reliable estimates of mutation rates from data, and they also need well-designed software tools to access these sophisticated algorithms.”

National Institute of Environmental Health Sciences: NIH Disaster Research Response program launches new website

National Institute of Environmental Health Sciences: NIH Disaster Research Response program launches new website. “For more than 20 years, the National Institute of Environmental Health Sciences (NIEHS) has played a lead role in our nation’s health research following oil spills, hurricanes, and other environmental calamities. Now, the institute is providing a new home for the Disaster Research Response (DR2) program and its vast collection of web-based resources needed for scientists to conduct vital and timely public health research in the aftermath of disasters. More than 500 curated research tools and resources are now organized into an easy-to-use online portal, available on the NIEHS website free of charge.”

The Straits Times: Singapore researchers invent new AI tool that could speed up diagnosis of heart disease

The Straits Times: Singapore researchers invent new AI tool that could speed up diagnosis of heart disease . “A new tool that could lead to faster diagnosis of heart disease has been invented by researchers in Singapore. Powered by artificial intelligence (AI), it uses electrocardiograms (ECGs) and has an accuracy rate of 98.5 percent. ECGs measure the electrical activity of heartbeats to detect heart abnormalities.”

University of Sydney: World-first multiple sclerosis global image database launched

University of Sydney: World-first multiple sclerosis global image database launched. “The new MSBase Imaging Repository (MSBIR) integrates state-of-the-art informatics with an AI analytics engine, fostering a new generation of imaging biomarkers for precision monitoring of MS. It is designed to securely house raw de-identified imaging data for MS patients from multiple sites globally that can be accessed by registered contributing research groups, bringing capacity and scalability to clinical MS imaging research.”

UPI: Massive data-sharing effort to help doctors diagnose rare diseases across Europe

UPI: Massive data-sharing effort to help doctors diagnose rare diseases across Europe. “Doctors and medical researchers in Europe have undertaken a massive data-sharing project they hope will aid the diagnosis of rare disease. In a series of papers, published Tuesday in the European Journal of Human Genetics, researchers demonstrated how reanalysis of genomic and phenotypic data from patients with rare diseases — when combined with wide-scale data sharing — can increased the odds of accurate diagnosis.”

EurekAlert: Maximizing cancer survival, minimizing treatment side effects with AI

EurekAlert: Maximizing cancer survival, minimizing treatment side effects with AI. “Computer scientists at the University of Illinois Chicago are developing a computational artificial intelligence system they hope will serve as a decision support tool for doctors prescribing treatment for head and neck cancer. The work is supported by a $2.8 million grant from the National Institutes of Health.”

Transparency International: Lack Of Transparency Over Vaccine Trials, Secretive Contracts And ‘science By Press Release’ Risk Success Of Global Covid-19 Response

Transparency International: Lack Of Transparency Over Vaccine Trials, Secretive Contracts And ‘science By Press Release’ Risk Success Of Global Covid-19 Response. “For Whose Benefit? is an in-depth study of the development and sale of the world’s top 20 COVID-19 vaccines, including those developed by AstraZeneca, Moderna and Pfizer/BioNTech. Through detailed analysis of clinical trial data and nearly 200 contracts for vaccine sales up to March 2021, the report reveals a pattern of poor transparency and a disturbing trend of governments censoring key details of their orders from drug companies.”

Duke Today: ’Smart Toilet’ Uses Artificial Intelligence To Monitor Bowel Health

Duke Today: ’Smart Toilet’ Uses Artificial Intelligence To Monitor Bowel Health. “An artificial intelligence tool being developed by Duke scientists can be added to the standard toilet to help analyze patients’ stool and give gastroenterologists the information they need to provide appropriate treatment for chronic issues such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).”

Medical Plastics News: FDA-approved medical devices and clinical trials database launched

Medical Plastics News: FDA-approved medical devices and clinical trials database launched. “The National Institute for Health Research’s Innovation Observatory (NIHRIO), based at Newcastle University, has launched a comprehensive database of searchable clinical trials drawing from 11 of the largest clinical trial registries in the world; as well as medical devices, diagnostics and digital applications information from the FDA database.”

University of Florida McKnight Brain Institute: AI tool to be tested for improved Parkinson’s diagnosis

University of Florida McKnight Brain Institute: AI tool to be tested for improved Parkinson’s diagnosis. “University of Florida researchers will broadly test a new artificial intelligence tool aimed at distinguishing the precise diagnosis for patients with early Parkinson’s disease or two related but distinct Parkinson’s-like syndromes under a new $5 million grant from the National Institutes of Health announced March 18.”